Market Cap
$111.4B
CVS
CVS HEALTH Corp
$85.50 ▲ +0.35%
Prev close $85.20Market cap$111.4B
ConsensusStrong Buy
12-mo target$116.28 (+36.5%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (8/10)34 New Institutional Positions16 Institutional Exits Consumer & Retail
Snapshot
The big-picture read on CVS right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (85%)
Inst. Holders
50 funds
Inst. Value
$90.8B
Inst. Activity
34 buys / 16 sells
Insider Activity
$0.00 buy / $359.0M sell
Insider Net $
-$359.0M
Social Sentiment
50° Neutral
SEC Reports
17
Press Releases
1
Congressional
5 trades
Price chart 30d -12.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 dividend
CVS Health declares quarterly dividend
WOONSOCKET, R.I., Sept. 30, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its boar
Aug 27, 2026 Event
Aug 5, 2026 SEC Lunsford v. CVS Health Corporation
Court ruling (caed) — Docket: 1:24-cv-00732
CVS Health reported strong Q2 2026 results with total revenues of $106.1 billion (+7.3% YoY) and Adjusted EPS of $2.58,
8-K — Impact 8/10
CVS Health announced a quarterly dividend of $0.665 per share, payable on August 3, 2026. This is a routine capital retu
Impact 2/10
A federal district court denied without prejudice CVS subsidiary Signify Health's motion to compel arbitration in a pro
COURT-RULING — Impact 2/10
Aetna (CVS subsidiary) won partial dismissal of a lawsuit by free-standing emergency centers (FECs) alleging underpaymen
COURT-RULING — Impact 5/10
Jun 30, 2026 Inst.
WELLINGTON MANAGEMENT GROUP LLP — ADD
33,801,113 shares ($3.5B)
Jun 30, 2026 Inst.
BANK OF AMERICA CORP — DOUBLED
23,188,670 shares ($2.4B)
Analyst ratings buy % +7.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
85% rate it Buy or better · 33 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 3, 2026 | UBS | MAINTAIN | Buy | 55% |
| Aug 19, 2026 | Argus Research | MAINTAIN | Buy | 54% |
| Aug 12, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 6, 2026 | UBS | MAINTAIN | Buy | 55% |
| Aug 6, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Aug 6, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Jul 25, 2026 | UBS | MAINTAIN | Buy | 55% |
| Jul 14, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Jul 13, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Jul 9, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 20 | 5 | 0 | 0 | 85% | |
| Aug 1, 2026 | 8 | 20 | 5 | 0 | 0 | 85% | |
| Jul 1, 2026 | 8 | 20 | 5 | 0 | 0 | 85% | |
| Jun 1, 2026 | 8 | 19 | 6 | 0 | 0 | 82% | |
| May 1, 2026 | 8 | 18 | 7 | 0 | 0 | 79% | |
| Apr 1, 2026 | 8 | 18 | 7 | 0 | 0 | 79% | |
| Mar 1, 2026 | 7 | 18 | 8 | 0 | 0 | 76% | |
| Feb 1, 2026 | 7 | 19 | 7 | 0 | 0 | 79% |
Price targets
Where 25 covering analysts think CVS trades over the next 12 months.
$116.28 +36.5% upside Strong Buy
Current$85.20 Low$103.00 Median$116.00 High$148.00 25 analysts
$103.00$148.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Social media sentiment mood -33.3%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
17 SEC filing reports analyzed · 6 bullish, 1 bearish, 0 mixed, 10 neutral · avg impact 4.0/10.Plus 1 press releases.
BULLISH8-K8/10
CVS Health reported strong Q2 2026 results with total revenues of $106.1 billion (+7.3% YoY) and Adj
Aug 5, 2026
NEUTRALCOURT-RULING2/10
A federal district court denied without prejudice CVS subsidiary Signify Health's motion to compel a
Jul 3, 2026
BULLISHCOURT-RULING5/10
Aetna (CVS subsidiary) won partial dismissal of a lawsuit by free-standing emergency centers (FECs)
Jul 3, 2026
NEUTRALCOURT-RULING3/10
In ER Addison LLC v. Aetna Health Inc., the court partially granted Aetna's motion to dismiss, dismi
Jul 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
dividend
CVS Health declares quarterly dividend
WOONSOCKET, R.I., Sept. 30, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend o
Sep 23, 2026
other
As measles cases rise in Tennessee, CVS Health® reminds residents that vaccines are available statewide
CVS Pharmacy® and MinuteClinic® offer MMR vaccinations to help protect eligible patients and communities WOONSOCKET, R.I., Sept. 23, 2026 /PRNewswire/
Sep 18, 2026
short_volume
Short Volume: CVS — 55.7% short (2.5M / 4.5M)
Short: 2,500,040 | Exempt: 1,161 | TRF Vol: 4,485,690 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
other
Aetna expands bundled oncology prior authorizations, easing provider burden and accelerating member access to care
Oncology bundling to support all eligible Medicaid members for all cancer types Full roll-out across all Aetna businesses in 2027 HARTFORD, Conn., Sep
Sep 7, 2026
dark_pool
Dark Pool: CVS — 4.3M shares, 84,598 trades
Week starting 2026-09-07. Total ATS volume: 4,278,334 shares across 84,598 trades.
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.62 | $1.46–$1.80 | 1.6% | -0.8% | 2↑ 18↓ | $104.6B | 22 |
| Next Q | $1.27 | $1.15–$1.40 | 16.4% | -1.3% | 6↑ 13↓ | $107.0B | 22 |
| Current FY | $8.04 | $7.94–$8.15 | 19.2% | +0.9% | 23↑ 0↓ | $417.8B | 25 |
| Next FY | $8.53 | $8.43–$9.05 | 6.0% | +0.3% | 17↑ 4↓ | $429.9B | 26 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.625 | — |
| 7d ago | $1.611 | +0.014 |
| 30d ago | $1.637 | -0.013 |
| 60d ago | $1.713 | -0.088 |
| 90d ago | $1.712 | -0.087 |
Institutional ownership
Which big funds own CVS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $90.8B total value (877,974,339 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, Capital. Net buying activity: 34 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 123,223,409 | $12.7B | 14.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 83,315,369 | $8.6B | 9.5% | — |
| Capital World Investors | 74,951,955 | $7.8B | 8.5% | — |
| STATE STREET CORP | 60,283,408 | $6.2B | 6.9% | — |
| DODGE & COX | 50,012,765 | $5.2B | 5.7% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 33,801,113 | $3.5B | 3.9% | ADD +49.8% |
| GEODE CAPITAL MANAGEMENT, LLC | 29,899,653 | $3.1B | 3.4% | — |
| FMR LLC | 28,920,617 | $3.0B | 3.3% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 26,637,259 | $2.8B | 3.0% | — |
| Capital Research Global Investors | 24,329,151 | $2.5B | 2.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 22,567,732 | 33,801,113 | +49.8% | $3.5B |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 9,351,969 | 23,188,670 | +148.0% | $2.4B |
| JPMORGAN CHASE & CO | TRIM | 29,527,125 | 22,112,970 | -25.1% | $2.3B |
| NORGES BANK | NEW | — | 18,038,922 | — | $1.9B |
| GQG Partners LLC | DOUBLED | 31,523 | 7,955,411 | +25136.8% | $823.0M |
| RAYMOND JAMES FINANCIAL INC | ADD | 3,459,485 | 4,348,680 | +25.7% | $449.9M |
| WELLS FARGO & COMPANY/MN | TRIM | 8,111,035 | 3,682,178 | -54.6% | $380.9M |
| VIKING GLOBAL INVESTORS LP | NEW | — | 3,663,361 | — | $379.0M |
| Holocene Advisors, LP | TRIM | 4,480,125 | 3,001,684 | -33.0% | $310.5M |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 1,920,910 | 2,902,944 | +51.1% | $300.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
21 insiders, 50 transactions. Net -$359.0M — $0.00 bought, $359.0M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | Clark James David | SVP, Cont & Chief Acct Officer | TAX W/H | 454 | $90.98 | $41.3K |
| May 31, 2026 | Compton-Phillips Amy | EVP, Chief Medical Officer | TAX W/H | 7,618 | $90.98 | $693.1K |
| May 31, 2026 | Newman Brian | EVP, Chief Financial Officer | TAX W/H | 2,478 | $90.98 | $225.4K |
| May 21, 2026 | ROBBINS LARRY | Director | SELL | 370,462 | $93.45 | $34.6M |
| May 21, 2026 | ROBBINS LARRY | Director | SELL | 378,000 | $93.31 | $35.3M |
| May 21, 2026 | AGUIRRE FERNANDO | Director | D | 1,563 | $93.50 | $146.1K |
| May 20, 2026 | ROBBINS LARRY | Director | SELL | 797,628 | $93.48 | $74.6M |
| May 20, 2026 | AGUIRRE FERNANDO | Director | D | 30,437 | $93.78 | $2.9M |
| May 20, 2026 | ROBBINS LARRY | Director | SELL | 152,691 | $94.81 | $14.5M |
| May 20, 2026 | ROBBINS LARRY | Director | SELL | 66,881 | $95.67 | $6.4M |
Congressional trades
CVS trades disclosed by members of Congress, with disclosure delay.
4 members · 3 buys / 2 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | CVS Health Corp | May 13, 2026(31d) |
| Feb 20, 2026 | Michael McCaul | R | HOUSE | BUY | $15,001 - $50,000 | CVS Health Corp | Mar 12, 2026(21d) |
| Jan 29, 2026 | John Boozman | R | SENATE | BUY | $1,001 - $15,000 | CVS Health Corp | Feb 15, 2026(18d) |
| Jan 13, 2026 | Michael McCaul | R | HOUSE | SELL | $15,001 - $50,000 | CVS Health Corp | Feb 12, 2026(31d) |
| Nov 21, 2025 | Dwight Evans | D | HOUSE | SELL | $1,001 - $15,000 | CVS Health Corp | May 18, 2026(179d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CVS.
Shares short
16,123,980
Settlement Sep 15, 2026
Change vs prior
-11.0%
Semi-monthly cycle
Days to cover
3.1
At avg daily volume
Of shares outstanding
≈1.3%
Estimate — not % of float
All CVS filing & press-release reports (18)
- 8-K reportAug 5, 2026
- PRESS-RELEASE reportJul 10, 2026
- COURT-RULING reportJul 3, 2026
- COURT-RULING reportJul 3, 2026
- COURT-RULING reportJul 3, 2026
- COURT-RULING reportJun 29, 2026
- COURT-RULING reportJun 9, 2026
- COURT-RULING reportJun 6, 2026
- COURT-RULING reportJun 3, 2026
- COURT-RULING reportMay 28, 2026
- S-3ASR reportMay 22, 2026
- COURT-RULING reportMay 19, 2026
- COURT-RULING reportMay 15, 2026
- COURT-RULING reportMay 15, 2026
- 8-K reportMay 6, 2026
- COURT-RULING reportApr 21, 2026
- COURT-RULING reportApr 14, 2026
- DEFA14A reportApr 3, 2026